Pfizer Inc. Recall: Quillivant XR methylphenidate HCl, for extended-release oral suspensio
Pfizer Inc. Recall: Quillivant XR methylphenidate HCl, for extended-release oral suspensio is one of 9,000 recalls in the RecallGuard dataset. Key details — Recalling firm: Pfizer Inc.; Product: Quillivant XR methylphenidate HCl, for extended-release oral suspension, 750mg/150 mL total volume (When constituted with 131
| Recalling firm | Pfizer Inc. |
|---|---|
| Product | Quillivant XR methylphenidate HCl, for extended-release oral suspension, 750mg/150 mL total volume (When constituted with 131 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted, Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-25. |
| Reason for recall | Failed Dissolution Specifications |
| Classification | Class III (least serious — unlikely to cause adverse health consequences) |
| Status | Terminated |
| Distribution | Nationwide |
| Recall initiated | 20170804 |
| Recall number | D-1164-2017 |
| Category | drug |
| State | NY |
| Country | United States |
$29/mo
Try RecallGuard →